Fate Therapeutics Inc SEC filings FATE
Fate Therapeutics Inc has 855 filings in SEC EDGAR's recent list, going back to May 2, 2008. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Nov 8, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 8, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 3, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 3, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 3, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 4, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Nov 4, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 4, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 5, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Nov 5, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | Aug 5, 2020 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 11, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Nov 5, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | Aug 6, 2019 | Jun 30, 2019 |
| 10-Q | Quarterly report | May 7, 2019 | Mar 31, 2019 |
| 10-Q/A | Amended quarterly report | Feb 8, 2019 | Sep 30, 2018 |
| 10-Q | Quarterly report | Nov 1, 2018 | Sep 30, 2018 |
| 10-Q | Quarterly report | Aug 6, 2018 | Jun 30, 2018 |
| 10-Q | Quarterly report | May 10, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Nov 1, 2017 | Sep 30, 2017 |
| 10-Q | Quarterly report | Aug 14, 2017 | Jun 30, 2017 |
| 10-Q | Quarterly report | May 15, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Nov 7, 2016 | Sep 30, 2016 |
| 10-Q | Quarterly report | Aug 8, 2016 | Jun 30, 2016 |
| 10-Q | Quarterly report | May 9, 2016 | Mar 31, 2016 |
| 10-Q/A | Amended quarterly report | Nov 6, 2015 | Jun 30, 2015 |
| 10-Q | Quarterly report | Nov 3, 2015 | Sep 30, 2015 |
| 10-Q | Quarterly report | Aug 5, 2015 | Jun 30, 2015 |
| 10-Q | Quarterly report | May 7, 2015 | Mar 31, 2015 |
| 10-Q | Quarterly report | Nov 12, 2014 | Sep 30, 2014 |
| 10-Q | Quarterly report | Aug 12, 2014 | Jun 30, 2014 |
| 10-Q | Quarterly report | May 13, 2014 | Mar 31, 2014 |
| 10-Q | Quarterly report | Nov 13, 2013 | Sep 30, 2013 |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FATE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434316
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.